Table 2.
Drug therapies administered to the groups of subjects as determined by the administration of bacteriotherapy.
| OB+ | OB– | ||||
|---|---|---|---|---|---|
| (N = 28) | (N = 42) | ||||
| Obs. | Values | Obs. | Values | p-value | |
| Administered drugs–no. (%) | |||||
| HCQ | 28 | 25 (89.3) | 42 | 40 (95.2) | 0.34 |
| TCZ | 28 | 7 (25) | 42 | 16 (38.1) | 0.25 |
| ABX | 28 | 11 (39.3) | 42 | 21 (50) | 0.38 |
| Administered drugs–no. (%) | 0.16 | ||||
| None | 28 | 2 (7.1) | 42 | 1 (2.4) | |
| One drug | 28 | 13 (46.4) | 42 | 11 (26.2) | |
| Two drugs | 28 | 9 (32.1) | 42 | 24 (57.1) | |
| Three drugs | 28 | 4 (14.3) | 42 | 6 (14.3) | |
| Combinations of drugs–no. (%) | |||||
| HCQ/TCZ/ABX | 28 | 4 (14.3) | 42 | 6 (14.3) | 1.0 |
| HCQ/TCZ | 28 | 2 (7.1) | 42 | 9 (21.4) | 0.11 |
| HCQ/ABX | 28 | 6 (21.4) | 42 | 15 (35.7) | 0.20 |
| STCZ/ABX | 28 | 1 (3.6) | 42 | 0 (0) | 0.22 |
A p ≤ 0.05 was considered statistically significant. ABX, antibiotics; HCQ, hydroxychloroquine; IRQ, interquartile range; Obs., number of available observations for each group; TCZ, Tocilizumab.